Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

ILLUMINATE Increasing Lutetium Production, While Leveraging Metabolic Imaging to Enhance Theranostics Effectiveness

Coordinator
Universitair Medisch Centrum Utrecht, Netherlands
Runs
1 October 2024 to 31 March 2029
Status
Running
EU funding
€11.6m
Total cost
€19.1m
Partners
15 organisations in 5 countries
Type
Research and Innovation Action
Grant agreement
101172722

What the project is doing

In the project's own words, from its summary on CORDIS.

Selective targeting of therapy with antibody-radioisotope combinations have led to major advances in treating cancers that are resistant to common therapies, such as castrate-resistant prostate cancer. Adding Lutetium-177-PSMA (Lu-177-PSMA) to standard care significantly prolongs survival. However, the increased use of Lu-177-based therapies has resulted in an increased demand for this isotope, leading to shortage risks.

In addition, despite the success of Lu-177-treatment, ~30% of patients do not benefit from treatment, but do suffer from side-effects. ILLUMINATE, will improve the availability and use of theranostics across its value chain by taking a hybrid approach: 1) Imaging capabilities will be improved by implementing novel, broadly applicable, scalable and highly effective Metabolic Magnetic Resonance Imaging (MeMRI), which are expected to give better and faster insight into treatment responses, allowing better patient stratificationand treatment personalisation; 2) The availability of Lu-177 will be fortified by improving its manufacturing process, and by developing sustainable production methods to help meet the general need for radio-isotope based therapies and increase EU autonomy.

The ILLUMINATE consortium (industries Philips, NRG, Bracco, TeslaDC, Wavetronica, Lygature, SDN, EuroBioImaging, and the Univerisities of Torino, Lund, Amsterdam UMC, Klinik Essen, coordinated by UMC Utrecht) uses the example of Lu-177-PSMA as a showcase clinical trial in 150 patients for broadly applicable innovative technologies in the field of theranostics and radioisotope manufacturing for oncology.

Who is involved

OrganisationCityCountryRole
Universitair Medisch Centrum UtrechtUtrechtNetherlandsCoordinator
Philips GmbHHamburgGermanyParticipant
Universitaetsklinikum EssenEssenGermanyParticipant
Euro-Bioimaging EricTurkuFinlandParticipant
Bracco Imaging SpAMilanoItalyParticipant
Consiglio Nazionale Delle RicercheRomaItalyParticipant
Synlab Sdn SRLNapoliItalyParticipant
Universita Degli Studi Di TorinoTorinoItalyParticipant
Nrg Pallas BVPettenNetherlandsParticipant
Philips Medical Systems Nederland BVBestNetherlandsParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Stichting LygatureUtrechtNetherlandsParticipant
Tesla Dynamic Coils BVZaltbommelNetherlandsParticipant
Wavetronica BVUtrechtNetherlandsParticipant
Lunds UniversitetLundSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI